Capstone Investment Advisors LLC Acquires Shares of 20,964 Denali Therapeutics Inc. $DNLI

Posted by Geri Gentry on Aug 29th, 2026

Capstone Investment Advisors LLC bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,964 shares of the company’s stock, valued at approximately $539,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in shares of Denali Therapeutics by 21.7% in the 1st quarter. Bank of America Corp DE now owns 1,134,183 shares of the company’s stock valued at $21,776,000 after acquiring an additional 202,039 shares during the period. Pictet Asset Management Holding SA lifted its stake in shares of Denali Therapeutics by 166.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,329,108 shares of the company’s stock worth $21,981,000 after purchasing an additional 829,946 shares during the last quarter. Great Lakes Advisors LLC bought a new stake in Denali Therapeutics during the second quarter valued at about $3,731,000. E. Ohman J or Asset Management AB bought a new stake in Denali Therapeutics during the second quarter valued at about $4,115,000. Finally, Sei Investments Co. purchased a new position in Denali Therapeutics in the first quarter valued at about $1,003,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider directly owned 281,763 shares in the company, valued at $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 9.70% of the company’s stock.

Denali Therapeutics Price Performance

Shares of DNLI opened at $24.00 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. The company’s fifty day moving average price is $24.62 and its 200-day moving average price is $21.72. Denali Therapeutics Inc. has a 1-year low of $12.58 and a 1-year high of $27.30. The firm has a market capitalization of $3.84 billion, a PE ratio of -8.45 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same period last year, the business earned ($0.72) EPS. On average, equities research analysts predict that Denali Therapeutics Inc. will post -2.67 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. UBS Group boosted their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Wedbush reiterated an “outperform” rating and set a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a research report on Monday, May 11th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $35.85.

View Our Latest Analysis on DNLI

Denali Therapeutics Profile

(Free Report)

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.